Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients

Inclusion Criteria: * Patient diagnosed with chronic fatigue syndrome or idiopathic chronic fatigue * Given written informed consent * Male or female aged between 20 and 65 * Patient who can read and answer to written questionnaires * Patient who agrees to visit clinic for study drug injection 3 times per a week for 6 weeks Exclusion Criteria: * Patient who has been administrated with any other investigational product for 28 days prior to screening visit * Patient who is pregnant or childbearing potential female patient who does not consent for contraception during the study * Patient who has a hypersensitivity provoked by study drug or others drived from animals * Patient who has been received with any human placenta product for 6 months before study participation * Abnormal liver function * Abnormal renal function * Back Depression Inventory (BDI) II is more than 29 * Underlying disease/conditions, in the investigator's judgment, which will be unable to participate in the study